Help us: Donate
Follow us on:




Organization Description

resTORbio is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of aging-related diseases. In september they merged with another company and now trade under the name Adicet Bio, Inc. They continue to develop RTB101, a small molecule product candidate, previously developed by resTORbio, that is a potent inhibitor of target of rapamycin complex 1 (TORC1).